Cargando…
Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up
As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable fo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718636/ https://www.ncbi.nlm.nih.gov/pubmed/34976939 http://dx.doi.org/10.3389/fpubh.2021.801609 |
_version_ | 1784624769688141824 |
---|---|
author | Coppola, Annachiara Buonerba, Carlo Cardinale, Davide Lo Conte, Gabriella Sansone, Donato Rofrano, Giuseppe De Vita, Sabato Morgante, Maria Triassi, Maria Atripaldi, Luigi Brambilla, Gianfranco Sabatino, Rocco Pierri, Andrea Pacella, Daniela Pizzolante, Antonio Pierri, Biancamaria Ferrucci, Veronica Zollo, Massimo Capasso, Mario Stringhini, Silvia Ascierto, Paolo Antonio Roperto, Sante Cerino, Pellegrino |
author_facet | Coppola, Annachiara Buonerba, Carlo Cardinale, Davide Lo Conte, Gabriella Sansone, Donato Rofrano, Giuseppe De Vita, Sabato Morgante, Maria Triassi, Maria Atripaldi, Luigi Brambilla, Gianfranco Sabatino, Rocco Pierri, Andrea Pacella, Daniela Pizzolante, Antonio Pierri, Biancamaria Ferrucci, Veronica Zollo, Massimo Capasso, Mario Stringhini, Silvia Ascierto, Paolo Antonio Roperto, Sante Cerino, Pellegrino |
author_sort | Coppola, Annachiara |
collection | PubMed |
description | As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8718636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87186362022-01-01 Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up Coppola, Annachiara Buonerba, Carlo Cardinale, Davide Lo Conte, Gabriella Sansone, Donato Rofrano, Giuseppe De Vita, Sabato Morgante, Maria Triassi, Maria Atripaldi, Luigi Brambilla, Gianfranco Sabatino, Rocco Pierri, Andrea Pacella, Daniela Pizzolante, Antonio Pierri, Biancamaria Ferrucci, Veronica Zollo, Massimo Capasso, Mario Stringhini, Silvia Ascierto, Paolo Antonio Roperto, Sante Cerino, Pellegrino Front Public Health Public Health As of November 17, 2021, SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2), the causative agent of COVID-19 (COronaVIrus Disease 19), has infected ~250 million people worldwide, causing around five million deaths. Titers of anti-SARS-CoV-2 neutralizing antibodies were relatively stable for at least 9 months in a population-based study conducted in Wuhan, China, both in symptomatic and in asymptomatic individuals. In the mass screening campaign conducted in the town of Ariano Irpino (Avellino, Italy) in May, 2020, 5.7% (95% CI: 5.3-6-1) of the 13,444 asymptomatic citizens screened were positive for anti-nucleocapsid antibodies against SARS-CoV-2. Among these, 422 citizens were re-tested for anti SARS-CoV-2 antibodies in January, 2021 and/or in April, 2021 and enrolled in this longitudinal observational study. Median (interquartile range) age of the study cohort was 46 years (29–59), with 47 (11.1%) participants of minor age, while 217 (51.4%) participants were females. There was no evidence of re-infection in any of the subjects included. Presence of anti-nuclear antibodies antibodies (Elecysis, Roche) was reported in 95.7 and 93.7% of evaluable participants in January and April, 2021. Multiple logistic regression analysis used to explore associations between age, sex and seroprevalence showed that adults vs. minors had significantly lower odds of having anti-S1 antibodies (Biorad) both in January, 2021 and in April, 2021. Our findings showed that antibodies remained detectable at least 11.5 months after infection in >90% of never symptomatic cases. Further investigation is required to establish duration of immunity against SARS-CoV-2. Frontiers Media S.A. 2021-12-17 /pmc/articles/PMC8718636/ /pubmed/34976939 http://dx.doi.org/10.3389/fpubh.2021.801609 Text en Copyright © 2021 Coppola, Buonerba, Cardinale, Lo Conte, Sansone, Rofrano, De Vita, Morgante, Triassi, Atripaldi, Brambilla, Sabatino, Pierri, Pacella, Pizzolante, Pierri, Ferrucci, Zollo, Capasso, Stringhini, Ascierto, Roperto and Cerino. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Coppola, Annachiara Buonerba, Carlo Cardinale, Davide Lo Conte, Gabriella Sansone, Donato Rofrano, Giuseppe De Vita, Sabato Morgante, Maria Triassi, Maria Atripaldi, Luigi Brambilla, Gianfranco Sabatino, Rocco Pierri, Andrea Pacella, Daniela Pizzolante, Antonio Pierri, Biancamaria Ferrucci, Veronica Zollo, Massimo Capasso, Mario Stringhini, Silvia Ascierto, Paolo Antonio Roperto, Sante Cerino, Pellegrino Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title | Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title_full | Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title_fullStr | Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title_full_unstemmed | Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title_short | Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up |
title_sort | durability of humoral immune responses to sars-cov-2 in citizens of ariano irpino (campania, italy): a longitudinal observational study with an 11.5-month follow-up |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718636/ https://www.ncbi.nlm.nih.gov/pubmed/34976939 http://dx.doi.org/10.3389/fpubh.2021.801609 |
work_keys_str_mv | AT coppolaannachiara durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT buonerbacarlo durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT cardinaledavide durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT locontegabriella durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT sansonedonato durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT rofranogiuseppe durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT devitasabato durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT morgantemaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT triassimaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT atripaldiluigi durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT brambillagianfranco durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT sabatinorocco durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT pierriandrea durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT pacelladaniela durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT pizzolanteantonio durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT pierribiancamaria durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT ferrucciveronica durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT zollomassimo durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT capassomario durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT stringhinisilvia durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT asciertopaoloantonio durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT ropertosante durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup AT cerinopellegrino durabilityofhumoralimmuneresponsestosarscov2incitizensofarianoirpinocampaniaitalyalongitudinalobservationalstudywithan115monthfollowup |